Results 71 to 80 of about 3,233,582 (249)

Fusogenic RNA Nanomodules for Fusion‐Mediated and Multiplexed siRNA Delivery

Advanced Functional Materials, EarlyView.
A fusogenic lipid‐layered RNA nanomodules (L‐CRAMs) enable high‐capacity and long‐lasting siRNA delivery through membrane fusion. These nanomodules carry exceptionally large siRNA payloads, avoid conventional endosomal uptake, and release multiple functional siRNAs through Dicer‐mediated processing.
Sunghyun Moon, Iksoo Jang, Taehyeon Kim, Nayoung Yoon, Kyuha Yum, Jong Bum Lee   +5 more
wiley   +1 more source

THE DIFFERENTIATED LIPID-LOWERING THERAPY IN WOMEN WITH CORONARY HEART DISEASE IN MENOPAUSE

Евразийский Кардиологический Журнал, 2012
The aim of the study: to assess the impact of differentiated lipid-lowering therapy on lipid metabolism, immune and inflammatory changes in women with stable angina in menopause.
N. A. Manak, O. A. Barbuk
doaj   +1 more source

A Holistic Platform Approach for Developing Robust Pulmonary mRNA Delivery: Integrating Novel Phenolic Acid‐Derived Ionizable Lipids and Device Engineering

Advanced Functional Materials, EarlyView.
An integrated pulmonary mRNA delivery platform combining novel biodegradable syringic acid‐derived ionizable lipids, design‐of‐experiments formulation optimization, and vibrating‐mesh nebulizer engineering enabled stable aerosolization and efficient lung delivery.
Neha Kaushal, Younan Ma, Asad Khanmohammed, Dipen Parande, Hanming Zhang, Saket Dolare, Juliet Chen, Apiwat Wangweerawong, Saswata Karmakar, Hongfeng Deng, Frank Koppenhagen, Shraddha Sharma, Eric Reyes, Sherry He, Lianne Boeglin, Caroline Woo, Azadeh Paksa, Ayed Allawzi, Anusha Dias, Gregory Troiano, Shrirang Karve, Frank DeRosa   +21 more
wiley   +1 more source

From Cell‐Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery

Advanced Healthcare Materials, EarlyView.
Biologically derived and hybrid nonviral nanovectors are examined as distinct but convergent design approaches. Integrating synthetic components with biologically functionalized membranes allows efficient interactions with complex cellular environments.
Clara Baldari, Claudia Leone, Gabriella Leccese, Claudia De Stradis, Alessandra Invidia, Concetta Quintarelli, Biagio De Angelis, Franco Locatelli, Giuseppe Gigli, Gabriele Maiorano, Ilaria Elena Palamà   +10 more
wiley   +1 more source

Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial

Journal of Lipid Research, 2017
Familial dysbetalipoproteinemia (FD) is a genetic disorder associated with impaired postprandial lipid clearance. The effect of adding bezafibrate to standard lipid-lowering therapy on postprandial and fasting lipid levels in patients with FD is unknown.
Charlotte Koopal, A. David Marais, Jan Westerink, Yolanda van der Graaf, Frank L.J. Visseren   +4 more
doaj   +1 more source

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

, 2023
In 2023 there are still even 75% of patients over the target of low-density lipoprotein cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored cardiovascular risk factor.
Banach M, Surma S, Stanisław Surma, Peter P. Toth, Toth PP, endorsed by the International Lipid Expert Panel (ILEP), Maciej Banach, Cicero AFG   +7 more
core   +1 more source

Water‐Activated Phospholipid Phase‐Separation Gel as an Immunomodulatory Anti‐Adhesion Barrier for Postoperative Adhesion Prevention

Advanced Healthcare Materials, EarlyView.
A water‐activated phospholipid phase‐separation gel is repurposed as a drug‐free surgical barrier for postoperative adhesion prevention. Propylene glycol promotes rapid lamellar gel reinforcement, prolonged local retention, and tissue coverage, while phosphatidylcholine‐mediated immunomodulation suppresses inflammatory and fibrotic responses. This dual‐
Jong‐Ju Lee, Yulseung Sung, Yeji Kim, Heesang Yang, Suyeon Pyo, Byeol Yun, Sung‐Joo Hwang   +6 more
wiley   +1 more source

Insufficient lipid-lowering therapy in the treatment of patients after acute coronary syndrome – there is room for improvement in the PCSK9 inhibitor era

Cardiologia Hungarica
Although the beneficial morbidity and mortality effects of lipid-lowering treatment have been demonstrated in numerous clinical trials, there is a significant gap between the guidelines and daily practice.
Gergely György Nagy, László Márk, Norbert Kiss, Andrea Gerencsér, György Rokszin, Ibolya Fábián, Dániel Aradi, László Bajnok, Zoltán Csanádi, István Karádi, István Reiber, György Paragh   +11 more
doaj   +1 more source

Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention

, 2023
Background: The RACING (randomized comparison of efficacy and safety of lipid-lowering with statin monotherapy versus statin/ezetimibe combination for high-risk cardiovascular diseases) trial examined the effects of combination therapy with moderate ...
최동훈, 홍명기, 김중선, 안철민, 남정모, 홍성진, 고영국, 김병극, 이승준, 박소희   +9 more
core   +1 more source

Human iPSC‐Derived Tissue‐Engineered Nigrostriatal Pathway for Chronic Restoration of Dopaminergic Axon Tracts in a Rat Parkinson's Model

Advanced Healthcare Materials, EarlyView.
Inspired by conventional cell therapy and emerging bioengineering approaches, the tissue‐engineered nigrostriatal pathway (TE‐NSP) has an anatomically‐inspired design comprising a population of human dopaminergic neurons with unidirectional, long‐projecting axon tracts.
Wisberty J. Gordián‐Vélez, Dimple Chouhan, Kevin D. Browne, James Lim, Saarang P. Karandikar, Rodrigo A. España, John E. Duda, H. Isaac Chen, D. Kacy Cullen   +8 more
wiley   +1 more source